Horizon Dx

Horizon Discovery is a leading global life science tools company that provides gene editing and gene modulation solutions to the biopharmaceutical industry. The company specializes in CRISPR, RNAi, and base editing technologies, offering a suite of products and services designed to accelerate drug discovery and development. Their diagnostics division, often referred to as Horizon Dx, is a market leader in providing highly characterized molecular reference standards (HDx) used to validate and monitor the performance of clinical assays. In December 2020, Horizon Discovery was acquired by PerkinElmer (now Revvity) for approximately $383 million, integrating its genomic engineering capabilities into a broader life sciences portfolio. The company continues to support researchers in understanding gene function and developing personalized medicines through its engineered cell lines and advanced genomic tools.